Abstract: A protease for activating the blood clotting factor VII is described, which (a) is inhibited by the presence of aprotinin, (b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and (c) in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa; and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band, which corresponds to a proenzyme, in the molecular weight range between 60 and 65 kDa.

Abstract: Handheld extruder welding device for welding thermoplastic synthetic materials, including an extruder screw, a drive system for the extruder screw in an axial extension of the extruder screw, and a hot air unit with a blower, where the blower and the drive system are integrated in a housing including several parts, and where a cooling body with air inlets is located on the housing on the screw side. This cooling body transfers the axial and radial forces between the drive system and the screw cylinder and supports the housing. In this handheld extruder welding device, all drive components are integrated in one housing which makes it suitable for robust use and a long service life. Its design with a cooling body as the support base for the entire device represents a special function.

Abstract: A handheld extruder welding device is provided for welding thermoplastic synthetic materials by means of an extrusion screw with a feed zone and a conveying/plasticizing zone. In the area of the feed zone, a feed channel with a ridge running in longitudinal direction is located in a sleeve. This ridge prevents the inserted plastic welding wire from twisting and looping inside and especially outside the handheld extruder welding device.

Abstract: A novel arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII-activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.

Abstract: A stabilized liquid preparation of a protease which activates blood coagulation Factor VII or of its proenzyme is herein described. The preparation also contains one or more compounds selected from the group consisting of ornithine, diaminopimelic acid, agmatine, creatine, guanidinoacetic acid, acetylornithine, citrulline, arginoinosuccinic acid, tranexamic acid and epsilon-aminocaproic acid or their salts and has a pH of 2–8.

Abstract: A novel arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII-activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.

Abstract: An electric motor having a stator with a plurality of radially arranged pole shoes between which slots are arranged, a rotor which rotates within the stator and has a rotor shaft which is mounted on both sides of the rotor, isolating stars for covering the end faces of the pole shoes, a stator winding which is situated in the slots and surrounds the end-face isolating stars, and an outer stator casing, in which the stator winding uses the isolating stars to secure the rotor and, at the respective end, encloses the rotor bearings and the rotor in its position in the stator. The isolating stars are formed such that they may firstly accommodate the bearings for the rotor shaft and furthermore also may accommodate bearings for attachment of supports for accommodating the electronic circuits for electronic commutation. An electric motor of this type is distinguished by the capability to operate for long periods continuously, accompanied by high rotational speeds and small dimensions.

Abstract: A handheld extruder welding device is provided for welding thermoplastic synthetic materials by means of an extrusion screw with a feed zone and a conveying/plasticizing zone. In the area of the feed zone, a feed channel with a ridge running in longitudinal direction is located in a sleeve. This ridge prevents the inserted plastic welding wire from twisting and looping inside and especially outside the handheld extruder welding device.

Abstract: Handheld extruder welding device for welding thermoplastic synthetic materials, including an extrusion screw with an attachment shaft and a device for the axial attachment of the extrusion screw with the attachment shaft to a gear-equipped drive system; where a one-piece gear housing for holding the gear is equipped with a front-side bearing flange for accepting the extrusion screw; where an output shaft arranged in the bearing flange has an output gear attached to it at the cup-side end and has an opening for inserting the attachment shaft; where a two-part annular clamping flange for clamping the extrusion screw in the bearing flange is provided; and where the clamping flange can be placed on the bearing flange from outside and can be clamped. In addition, the clamping flange may contain at least one feed channel for the welding wire. This design offers a compact, stable, and short gear output where the extrusion screw can be exchanged easily.

Abstract: Handheld extruder welding device for welding thermoplastic synthetic materials, including an extruder screw, a drive system for the extruder screw in an axial extension of the extruder screw, and a hot air unit with a blower, where the blower and the drive system are integrated in a housing including several parts, and where a cooling body with air inlets is located on the housing on the screw side. This cooling body transfers the axial and radial forces between the drive system and the screw cylinder and supports the housing. In this handheld extruder welding device, all drive components are integrated in one housing which makes it suitable for robust use and a long service life. Its design with a cooling body as the support base for the entire device represents a special function.

Abstract: A protease for activating the blood clotting factor VII is described, which (a) is inhibited by the presence of aprotinin, (b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and (c) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more brands in the molecular weight range from 50 to 75 kDa and kDa in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa. The proenzyme of this protease is also characterized. Further, a process for obtaining this protease and its use in hemorrhage prophylaxis or hemostasis is described. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described.

Abstract: A protease for activating the blood clotting factor VII is described, wherein the protease is inhibited by the presence of aprotinin and is increased in its activity by calcium ions and/or heparin or heparin-related substances, and wherein in SDS-PAGE, on subsequent staining in the non-reduced state, the protease has one or more brands in the molecular weight range from 50 to 75 kDa, and in the reduced state, the protease has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa. The proenzyme of this protease is also characterized. Further, a process for obtaining this protease and its use in hemorrhage prophylaxis or hemostasis is described. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described.

Abstract: An electric motor having a stator with a plurality of radially arranged pole shoes between which slots are arranged, a rotor which rotates within the stator and has a rotor shaft which is mounted on both sides of the rotor, isolating stars for covering the end faces of the pole shoes, a stator winding which is situated in the slots and surrounds the end-face isolating stars, and an outer stator casing, in which the stator winding uses the isolating stars to secure the rotor and, at the respective end, encloses the rotor bearings and the rotor in its position in the stator. The isolating stars are formed such that they may firstly accommodate the bearings for the rotor shaft and furthermore also may accommodate bearings for attachment of supports for accommodating the electronic circuits for electronic commutation. An electric motor of this type is distinguished by the capability to operate for long periods continuously, accompanied by high rotational speeds and small dimensions.

Abstract: Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutant comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, is described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Furthermore, diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.

Abstract: Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.

Abstract: A process for the preparation in pure form of the protease activating blood clotting factor VII and/or its proenzyme is described in which these are obtained from biological fluids or those obtained in the case of preparation by genetic engineering

Abstract: A stabilized protein preparation is described which contains no antithrombin III and is protected against loss of activity during pasteurization by the addition of stabilizers which comprise one or more saccharides as a mixture with more than 0.5 mol/l of one or more amino acids chosen from the group arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts or glutamic acid and its salts. Glycine and/or glutamine can also be additionally added to each of these amino acids. A process for the viral inactivation or viral depletion of a protein preparation of this type which contains the abovementioned stabilizers and is subjected to pasteurization or viral depletion by filtration, centrifugation or treatment with detergents or bactericidal or virucidal agents is also described.

Abstract: A stabilized protein preparation is described which contains no antithrombin III and is protected against loss of activity during pasteurization by the addition of stabilizers which comprise one or more saccharides as a mixture with more than 0.5 mol/l of one or more amino acids chosen from the group arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts or glutamic acid and its salts. Glycine and/or glutamine can also be additionally added to each of these amino acids. A process for the viral inactivation or viral depletion of a protein preparation of this type which contains the abovementioned stabilizers and is subjected to pasteurization or viral depletion by filtration, centrifugation or treatment with detergents or bactericidal or virucidal agents is also described.

Abstract: A process for the preparation in pure form of the protease activating blood clotting factor VII and/or its proenzyme by use of one or more affinity chromatography separation processes and/or fractional precipitation is described, in which the affinity chromatography separation process used is adsorption on

Abstract: A novel arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII-activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.